Logo image of TGEN

TECOGEN INC/WALTHAM MA (TGEN) Stock Fundamental Analysis

USA - NYSEARCA:TGEN - US87876P2011 - Common Stock

7.85 USD
-0.32 (-3.92%)
Last: 9/26/2025, 8:04:01 PM
8.05 USD
+0.2 (+2.55%)
After Hours: 9/26/2025, 8:04:01 PM
Fundamental Rating

3

Taking everything into account, TGEN scores 3 out of 10 in our fundamental rating. TGEN was compared to 41 industry peers in the Building Products industry. The financial health of TGEN is average, but there are quite some concerns on its profitability. TGEN is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

TGEN had negative earnings in the past year.
TGEN had a positive operating cash flow in the past year.
In the past 5 years TGEN reported 4 times negative net income.
The reported operating cash flow has been mixed in the past 5 years: TGEN reported negative operating cash flow in multiple years.
TGEN Yearly Net Income VS EBIT VS OCF VS FCFTGEN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2M -2M 4M -4M -6M

1.2 Ratios

With a Return On Assets value of -15.31%, TGEN is not doing good in the industry: 87.80% of the companies in the same industry are doing better.
Looking at the Return On Equity, with a value of -46.53%, TGEN is doing worse than 87.80% of the companies in the same industry.
Industry RankSector Rank
ROA -15.31%
ROE -46.53%
ROIC N/A
ROA(3y)-13.51%
ROA(5y)-9.91%
ROE(3y)-30.18%
ROE(5y)-21.73%
ROIC(3y)N/A
ROIC(5y)N/A
TGEN Yearly ROA, ROE, ROICTGEN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40

1.3 Margins

The Gross Margin of TGEN (43.64%) is better than 82.93% of its industry peers.
In the last couple of years the Gross Margin of TGEN has grown nicely.
The Profit Margin and Operating Margin are not available for TGEN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 43.64%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.79%
GM growth 5Y3.17%
TGEN Yearly Profit, Operating, Gross MarginsTGEN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40

More info and screens

5

2. Health

2.1 Basic Checks

TGEN does not have a ROIC to compare to the WACC, probably because it is not profitable.
TGEN has more shares outstanding than it did 1 year ago.
The number of shares outstanding for TGEN has been increased compared to 5 years ago.
The debt/assets ratio for TGEN is higher compared to a year ago.
TGEN Yearly Shares OutstandingTGEN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
TGEN Yearly Total Debt VS Total AssetsTGEN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

TGEN has an Altman-Z score of 5.03. This indicates that TGEN is financially healthy and has little risk of bankruptcy at the moment.
TGEN has a better Altman-Z score (5.03) than 65.85% of its industry peers.
TGEN has a debt to FCF ratio of 0.63. This is a very positive value and a sign of high solvency as it would only need 0.63 years to pay back of all of its debts.
With an excellent Debt to FCF ratio value of 0.63, TGEN belongs to the best of the industry, outperforming 87.80% of the companies in the same industry.
A Debt/Equity ratio of 0.18 indicates that TGEN is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.18, TGEN is in the better half of the industry, outperforming 68.29% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.18
Debt/FCF 0.63
Altman-Z 5.03
ROIC/WACCN/A
WACC10.41%
TGEN Yearly LT Debt VS Equity VS FCFTGEN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M 20M 30M

2.3 Liquidity

TGEN has a Current Ratio of 1.32. This is a normal value and indicates that TGEN is financially healthy and should not expect problems in meeting its short term obligations.
TGEN's Current ratio of 1.32 is on the low side compared to the rest of the industry. TGEN is outperformed by 80.49% of its industry peers.
A Quick Ratio of 0.74 indicates that TGEN may have some problems paying its short term obligations.
TGEN has a worse Quick ratio (0.74) than 85.37% of its industry peers.
Industry RankSector Rank
Current Ratio 1.32
Quick Ratio 0.74
TGEN Yearly Current Assets VS Current LiabilitesTGEN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for TGEN have decreased strongly by -220.48% in the last year.
TGEN shows a small growth in Revenue. In the last year, the Revenue has grown by 2.46%.
Measured over the past years, TGEN shows a decrease in Revenue. The Revenue has been decreasing by -5.52% on average per year.
EPS 1Y (TTM)-220.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)2.46%
Revenue growth 3Y-9.23%
Revenue growth 5Y-5.52%
Sales Q2Q%54.33%

3.2 Future

The Earnings Per Share is expected to grow by 38.30% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 22.20% on average over the next years. This is a very strong growth
EPS Next Y-53%
EPS Next 2Y-23.69%
EPS Next 3Y-20.14%
EPS Next 5Y38.3%
Revenue Next Year-2.95%
Revenue Next 2Y8.41%
Revenue Next 3Y1.41%
Revenue Next 5Y22.2%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
TGEN Yearly Revenue VS EstimatesTGEN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 20M 40M 60M 80M 100M
TGEN Yearly EPS VS EstimatesTGEN Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.2 -0.2 0.4 0.6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

TGEN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TGEN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TGEN Price Earnings VS Forward Price EarningsTGEN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 -40 -60

4.2 Price Multiples

73.17% of the companies in the same industry are cheaper than TGEN, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 75.39
EV/EBITDA N/A
TGEN Per share dataTGEN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6

4.3 Compensation for Growth

A cheap valuation may be justified as TGEN's earnings are expected to decrease with -20.14% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-23.69%
EPS Next 3Y-20.14%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TGEN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TECOGEN INC/WALTHAM MA

NYSEARCA:TGEN (9/26/2025, 8:04:01 PM)

After market: 8.05 +0.2 (+2.55%)

7.85

-0.32 (-3.92%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryBuilding Products
Earnings (Last)08-12 2025-08-12/amc
Earnings (Next)11-11 2025-11-11
Inst Owners15.06%
Inst Owner Change30821.9%
Ins Owners23.08%
Ins Owner Change5.96%
Market Cap233.07M
Analysts82.86
Price Target15.3 (94.9%)
Short Float %6.22%
Short Ratio1.2
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-31.96%
Min Revenue beat(2)-33.4%
Max Revenue beat(2)-30.52%
Revenue beat(4)0
Avg Revenue beat(4)-30.88%
Min Revenue beat(4)-39.65%
Max Revenue beat(4)-19.94%
Revenue beat(8)2
Avg Revenue beat(8)-17.83%
Revenue beat(12)3
Avg Revenue beat(12)-15.77%
Revenue beat(16)4
Avg Revenue beat(16)-15.85%
PT rev (1m)0%
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-189.47%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-49.71%
Revenue NY rev (3m)-49.71%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 10.3
P/FCF 75.39
P/OCF 57.4
P/B 22.78
P/tB 43.4
EV/EBITDA N/A
EPS(TTM)-0.1
EYN/A
EPS(NY)-0.15
Fwd EYN/A
FCF(TTM)0.1
FCFY1.33%
OCF(TTM)0.14
OCFY1.74%
SpS0.76
BVpS0.34
TBVpS0.18
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -15.31%
ROE -46.53%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 43.64%
FCFM 13.67%
ROA(3y)-13.51%
ROA(5y)-9.91%
ROE(3y)-30.18%
ROE(5y)-21.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.79%
GM growth 5Y3.17%
F-Score4
Asset Turnover0.73
Health
Industry RankSector Rank
Debt/Equity 0.18
Debt/FCF 0.63
Debt/EBITDA N/A
Cap/Depr 175.01%
Cap/Sales 4.28%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.32
Quick Ratio 0.74
Altman-Z 5.03
F-Score4
WACC10.41%
ROIC/WACCN/A
Cap/Depr(3y)87.45%
Cap/Depr(5y)67.63%
Cap/Sales(3y)1.94%
Cap/Sales(5y)1.42%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-220.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y-53%
EPS Next 2Y-23.69%
EPS Next 3Y-20.14%
EPS Next 5Y38.3%
Revenue 1Y (TTM)2.46%
Revenue growth 3Y-9.23%
Revenue growth 5Y-5.52%
Sales Q2Q%54.33%
Revenue Next Year-2.95%
Revenue Next 2Y8.41%
Revenue Next 3Y1.41%
Revenue Next 5Y22.2%
EBIT growth 1Y2.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year3.59%
EBIT Next 3Y70.17%
EBIT Next 5YN/A
FCF growth 1Y457.51%
FCF growth 3Y112.98%
FCF growth 5YN/A
OCF growth 1Y596.53%
OCF growth 3Y105.19%
OCF growth 5YN/A